Market Drivers

The rising prevalence of chronic diseases

A huge growth force in Global Drug Delivery Market is the cardiovascular disease, cancer, chronic respiratory disease and diabetes pandemic. The World Health Organization (WHO) claims that a small number of 43 million deaths in 2021 alone are caused by NCDs, comprising 75 percent of all the global non-pandemic death toll. In low/ middle-income countries, 73 per cent of death was caused by NCDs. More than 19 million deaths were caused by cardiovascular disease, 10 million cancers, 4 million chronic respiratory disease, and more than 2 million diseases related to diabetes, which includes diabetes-related kidney disease. The four of these types of diseases resulted in the 80 percent of the overall premature NCD death. The rise in disease burden of NCDs also equates to a burning need towards patient-centric drug delivery systems that are effective when it comes to sustaining chronic long-term disease delivery.

Improvement of medication adherence through advancement of parenteral pens, inhalers, transdermal patch delivery systems, injection pens, smart drug delivery systems can enhance the health outcome of the person. Every bad habit in the way of life, every tobacco, every alcohol abuse, wrong diet, physical insufficiency, and air pollution put a lot more sense into early care, continuity of treatment, and drug administration. The WHO also emphasizes on screening, palliative care, and real-time treatment as some of the measures that are meant to control mortality of NCDs. This translated into an even higher rate of incidence of chronic disease, and as more people everywhere in the world are seeking and getting treatment, and more so in resource-scarce settings, the need is likely to grow exponentially to have methods and systems of drug administration that can be scalable, user-friendly, and as such, accommodation within drug delivery system component to become the much-needed centre of modern health response strategies.

Market Restraints

High development and regulatory costs

High development cost and regulatory cost of advanced drug delivery devices belong to one of the greatest challenges. Giant R&D, extremely complex clinical trials, and burdensome regulatory clearances are required to discover the new delivery technology such as nanocarriers, microneedles, or implantable gadgets which replay the pace of entry and obsessively contribute to cost-related pressures. The second largest problem is the complexity of the devise and user compliance, especially where home-care or self-administration is used. Despite all the desirable developments that the drug delivery products have undergone to become more patient friendly, patient or drug abuse, dosing mistakes on the part of the patient, or patient poor compliance may diminish therapeutic dose. This is particularly of concern when dealing with geriatric patients or physically and mentally incapacitated patients. Making the problem worse, there is also the issue of scalability and production especially with novice modes of delivery such as bioologics or gene therapy where a highly restricted and sterile manufacturing centers are required. 

The other one is to maintain APIs stable when in storage and transportation, the most advanced products are heat-stable, humidity-sensitive, or light-sensitive. Accessibility and affordability remain a concern in low and middle income countries where the inability to afford and infrastructure can exclude the deployment of the advanced drug delivery technology. Poor staffing of skilled health care providers and adequate education of patients are some of the challenges that interfere with successful adoption in those countries.

By Type

In 2024, Oral Drug Delivery type captured 44.00% of market sales.

By End Use

In 2024, Hospitals & Clinics segment dominated in End Use segment.

In the End Use category of Global Drug Delivery Market Hospitals & Clinics segment prevailed in the year 2024 as they are the hub of advanced medication, surgery, and inpatient medication administration, specially injectable and intravenous drug administration. Hospitalization of both chronic and acute diseases is on the rise which is the need to this segment. There is also a stable growth in Home Healthcare as a result of aged populations, chronic illness management and growing preference to self-administering devices that self administer with an insulin pen, an inhaler and a patch among others. Home Healthcare offers cost effective services, which are convenient to the patients in a non-clinical setting. ASCs are a new type of the category as there is the augmentation of the same-day procedures that require appropriate drug delivery to manage pain, anesthesia, and recovery.

By Geography

North America dominates the drug delivery market with estimated market value of USD 836.99 Million in 2024, and is expected to reach USD 1,388.54 Million in 2032.

According to a Centers for Disease Control and Prevention (CDC) report, approximately 6 out of every 10 adult Americans are chronically ill and, currently, accounts for over four point five trillion U.S. annual health spending, alone. There is also an increased use of the self-injection and home care market, which drives the market in the broad arena of convenient delivery devices such as pre-filled syringes, auto-injectors, and transdermal patches. The shift does not only improve patient compliance but also reduces workload on the medical facility.

List of Top Players

• Johnson & Johnson (Janssen Pharmaceuticals)
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• AbbVie Inc.
• AstraZeneca plc
• 3M Health Care
• Becton, Dickinson and Company (BD)
• Antares Pharma (Halozyme Therapeutics)
• Novartis AG
• Others

Key Industry Developments

• Chinese biotech companies such as 3SBio, Akeso, and Hansoh Pharma in July 2025 inked huge international licensing agreements with Merck and Pfizer. This rally, as captured in a 62% surge in the Hang Seng Biotech Index, is fueled by euphoria over PD-1 and PD-1/VEGF cancer treatments that increase international access to cheap but complex therapy.
• Varda Space Industries raised $187 million in Series C financing in July 2025 to scale up its production of drug crystals in space. With microgravity in SpaceX capsules, the startup developed better crystal shapes, such as a new ritonavir form, and is expanding into biologics and antibodies as well.
• In July 2025, Merck & Co. bought Verona Pharma for $10 billion, taking on the FDA-approved inhaled therapy Ohtuvayre in its pipeline. The drug, aimed at COPD, is expected to have ~$2.6 billion sales in 2030 in the U.S., adding strength to Merck's respiratory and drug delivery pipeline.
   

Table of Contents

1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. MARKET INTRODUCTION
   2. MARKET DRIVERS
   3. MARKET RESTRAINTS
   4. FUTURE OPPORTUNITIES
   5. MARKET TRENDS
   6. PORTER’S FIVE FORCES ANALYSIS
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Suppliers
      4. Bargaining Power of Buyers
      5. Intensity of Competitive Rivalry
   7. VALUE CHAIN & PROFIT MARGIN ANALYSIS
   8. PRICING ANALYSIS
   9. REGULATORY FRAMEWORK
   10. COVID-19 IMPACT ANALYSIS
   11. PRODUCT LIFE CYCLE ANALYSIS
   12. PESTLE ANALYSIS
   13. MICRO ECONOMIC ANALYSIS
   14. Market Premium Insights (Enterprise license)
       • Consumer Analysis (List of Potential Consumers)
       • Top 10 Country-Wise Import & Export Data (If Applicable)
       • Regulatory Bodies & Authorization Across the Globe
       • Key Conferences & Events: Next Two Years
       • Top Patents for The Market
5. GLOBAL DRUG DELIVERY MARKET REVENUE & SHARE ANALYSIS (2023-2032)
   1. By Type
      1. Oral Drug Delivery
      2. Injectable Drug Delivery
      3. Transdermal Drug Delivery
      4. Inhalation Drug Delivery
      5. Others
   2. By Distribution Channel 
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   3. By Application 
      1. Cancer
      2. Diabetes
      3. Cardiovascular Diseases
      4. Respiratory Diseases 
      5. Others
   4. By End Use
      1. Hospitals & Clinics
      2. Home Healthcare
      3. Ambulatory Surgical Centers (ASCs)

1. GLOBAL DRUG DELIVERY MARKET REVENUE & SHARE ANALYSIS (2023-2032), BY REGION
   1. NORTH AMERICA 
      1. U.S.
      2. Canada
      3. Mexico
   2. EUROPE
      1. Germany
      2. UK
      3. France
      4. Italy
      5. Spain
      6. Rest of Europe
   3. ASIA PACIFIC 
      1. China
      2. Japan
      3. India
      4. South Korea
      5. Rest of APAC
   4. MIDDLE EAST & AFRICA
      1. GCC
      2. South Africa
      3. Rest of MEA
   5. LATIN AMERICA
      1. Brazil
      2. Argentina
      3. Rest of LATAM

For all the segments and sub-segments, Qualitative as well as Quantitative data will be provided. In Quantitative we provide the historic (2023), base (2024), estimated (2025) and forecasted (2025-2032) market value in USD Million, Share in % with a CAGR (2025-2032). This data would be provided on a regional as well as country level.

1. COMPETITIVE LANDSCAPE
   1. OVERVIEW
   2. KEY PLAYERS MARKET SHARE ANALYSIS
   3. LIST OF KEY STRATEGIC DEVELOPMENTS 
2. COMPANY PROFILES
   1. JOHNSON & JOHNSON (JANSSEN PHARMACEUTICALS)
      1. Company Overview
      2. Company Financial Insights (Total Revenue, Revenue By Business Segments, and By Region)
      3. Product Benchmarking
      4. Key Strategic Developments (Merges & Acquisitions, Partnership /Agreements/Joint Venture, Expansion, New Product Launches, and other developments)
      5. Business Strategic Overview
      6. SWOT Analysis
   2. Pfizer Inc.
   3. F. Hoffmann-La Roche Ltd.
   4. Merck & Co., Inc.
   5. AbbVie Inc.
   6. AstraZeneca plc 
   7. 3M Health Care 
   8. Becton, Dickinson and Company (BD)
   9. Antares Pharma (Halozyme Therapeutics)
   10. Novartis AG
3. LIST OF SOURCES
4. DISCLAIMER